相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1
Ken-ichi Fujita et al.
CANCER SCIENCE (2008)
The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer
Y. Kaida et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Potential regional differences for the tolerability profiles of fluoropyrimidines
Daniel G. Haller et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
Shinichi Sakuramoto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence
V Malaiyandi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: Joint United States and Japan study of UFT/LV
K Shirao et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Prediction of irinotecan pharmacokinetics by use of cytochrome p450 3A4 phenotyping probes
RHJ Mathijssen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors
GJ Peters et al.
CLINICAL CANCER RESEARCH (2004)
A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity
M Pitarque et al.
HUMAN MUTATION (2004)
Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro
R Yoshida et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies
BC Goh et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
A novel single nucleotide polymorphism altering stability and activity of CYP2A6
N Ariyoshi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans
M Nakajima et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
分享论文
